Amgen’s Nplate (Romiplostim) Receives FDA’s Approval for Immune Thrombocytopenia Aged 1 year and Older

 Amgen’s Nplate (Romiplostim) Receives FDA’s Approval for Immune Thrombocytopenia Aged 1 year and Older

Amgen’s Nplate (Romiplostim) Receives FDA’s Approval for Immune Thrombocytopenia Aged 1 year and Older

Shots:
  • The approval is based on P-III & P-I/II study results assessing Nplate vs PBO in pediatric patients with Immune Thrombocytopenia (ITP) for at least six months who had no response to corticosteroids, immunoglobulins or splenectomy
  • The  P-III & P-I/II study demonstrated increase in overall platelet response (71% vs 20%) with durable platelet response (52% vs 10%)
  • Nplate is a thrombopoietin (TPO) receptor agonist approved in 67 countries including the US and EU for increase in platelet count for patients with ITP

Click here to read full press release/ article | Ref: Amgen | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post